Haydom Lutheran Hospital
Haydom, Manyara Region, Tanzania
NCT Number: NCT03268902
This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.
Looking for future studies?
Notify Me0 day–14 day
All sexes
Interventional
Phase 2 / Phase 3
Haydom, Manyara Region, Tanzania
Children living in rural sub-Saharan Africa experience massive challenges to child thriving, with poor linear growth and delays in child development. In a cohort of 211 children living in the rural Haydom area of Tanzania (participating in the Interactions of Malnutrition & Enteric Infections: Consequences for Child Health and Development "MAL-ED" Study), 70.6% had stunted growth at 18 months. This rate of moderate and severe stunting (length-for-age z-score [HAZ] <-2 standard deviations) was the highest of the 8 study sites in MAL-ED.
This enormous deficit is likely associated with high rates of enteric infections with Campylobacter, E. coli pathotypes, Cryptosporidium, and Giardia, organisms susceptible to azithromycin and/or nitazoxanide. Infections such as these occur frequently in developing areas and are often associated with environmental enteropathy, including ongoing enteric inflammation and loss of enterocyte integrity, leading to possible bacterial translocation and poorer absorption of ingested nutrients. The consequences of these infections, enteric dysfunction and poor nutrient absorption frequently include growth stunting, learning delays, and an overall loss of human capital.
Emerging evidence suggests a potential role for the tryptophan-niacin pathway (including the end-product nicotinamide, an isoform of vitamin B3) in decreasing mucosal inflammation and affecting enteral microbiota. At the Tanzania site of MAL-ED, serum levels of tryptophan were related to subsequent linear growth, further suggesting importance of the tryptophan-niacin pathway. What is not clear is whether early childhood growth and development could be improved by targeting enteric infection and the tryptophan-niacin pathway by 1) delivering antibiotics against specific bacteria and/or 2) providing vitamin B3 as nicotinamide/niacinamide.
The main analysis will be intention-to-treat but a secondary analysis will be per protocol.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
Other names: Throza DPS
Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
Other names: Alinia
Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.
Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age
Other names: Vitamin B3
Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.
Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.
Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Time frame: 18 months
Time frame: 18 months
Time frame: 18 months
Time frame: 18 months
HAZ <-2
Time frame: 0-18 months
Time frame: 0-18 months
Time frame: 0-18 months
Incidence of diarrhea, lower respiratory infection and febrile illness
Time frame: 12 and 18 months
Moderate to severe anemia by WHO definition for age and altitude
Time frame: 6, 6.5, 12, 12.5, 18 months
Time frame: 6, 6.5, 12, 18 months
Composition of intestinal microbiome
Time frame: 6, 12, 18 months
Stool myeloperoxidase ELISA
Time frame: 12 and 18 months
High-sensitivity CRP concentration
Time frame: 12 and 18 months
Time frame: 12 and 18 months
Time frame: 12 and 18 months
Ratio of tryptophan concentration to kynurenine concentration in metabolomic testing
Time frame: 6, 12, 18 months
Concentration of downstream metabolites of niacin and nicotinamide as tested by metabolomic analysis
Time frame: 6, 12 and 18 months
Prevalence of SIBO as tested via exhaled hydrogen
Time frame: 18 months
The MDAT is a measure of child cognitive development
Haydom Lutheran Hospital
Other
Acronym: ELICIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06642012
Body Weight, Body Weight Changes
Baltimore, Maryland, United States
View Trial DetailsNCT00970866
Anemia, Growth Disorders
Agomanya, Ghana
View Trial DetailsNCT00524446
Communication Disorders, Developmental Delay
Mangochi, Malawi
View Trial DetailsNCT05793294
Body Weight, Body Weight Changes
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial Details